Traws Pharma Profit Margin

Traws Pharma posts a profit margin of -71375.16% as of May 2026. That compares with -73682.74% in the prior-year period — up 3.1% year over year. That is below the Healthcare sector average of 13.89%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Traws Pharma's profit margin was -73682.74%. The latest reading is -71375.16% — a 3.1% year-over-year increase (period ending May 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 13.89% is typical. Traws Pharma's -71375.16% is lower that level. That is roughly 513846.3% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Traws Pharma's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -71375.16% as of May 2026; use YoY and peer views to separate noise from signal.

Context for TRAW's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.89%), and (3) consistency with growth and profitability. This page covers the first two; Traws Pharma's other metric pages and overview cover the third.